INDICATIONS     CONTRA-INDICATIONS     DOSAGE     SIDE-EFFECTS     PREGNANCY     OVERDOSE     IDENTIFICATION     PATIENT INFORMATION

Logo ADCO-QUININE DIHYDROCHLORIDE 300 mg/mL

SCHEDULING STATUS:
S4

PROPRIETARY NAME
(and dosage form):

ADCO-QUININE DIHYDROCHLORIDE 300 mg/mL
INJECTION

COMPOSITION:
Each 1 mL ampoule contains:
Quinine dihydrochloride         300 mg

PHARMACOLOGICAL CLASSIFICATION:
A. 20.2.6 Medicines against Protozoa

PHARMACOLOGICAL ACTION:
Quinine acts primarily as a schizontocide ie it suppresses the asexual cycle of development of malaria parasites in the erythrocytes. It has little effect on sporozoites or pre-erythrocytic forms of malarial parasites. It does not, therefore, prevent the relapse of Plasmodium vivax infections.
Quinine is also gametocidal for P. vivax and P. malariae but not for P. falciparum, and therefore does not prevent transmission of this infection by the mosquito.
Plasma concentrations of quinine between 8 and 15 mg/litre are effective clinically and are generally non-toxic; such values are usually achieved with the standard therapeutic dose.
Approximately 70% of quinine is bound to proteins in the plasma in healthy subjects, rising to about 90% in patients with malaria. The concentration in cerebrospinal fluid is about 2-5% of that in the plasma. Quinine is extensively metabolized, especially in the liver, and excreted in the urine. Estimates of the proportion of unchanged quinine excreted in the urine vary from less than 5% to 20%.
The metabolites are excreted in the urine; renal excretion of quinine is twice as rapid when the urine is acidic as when it is alkaline.
The elimination half-life in healthy subjects is about eleven hours, but may be prolonged in patients with malaria.
The pharmacokinetics of quinine may be altered significantly by malaria infection, with reductions in both clearance and the apparent volume of distribution.
Quinine crosses the placenta and is excreted in breast milk.

INDICATIONS:
For the treatment of acute attacks of malaria, including attacks due to chloroquine-resistant or multi-drug-resistant strains of Plasmodium falciparum.
Quinine is used parenterally for cerebral, severe or complicated malaria, or when vomiting prevents retention of an orally administered drug.
Quinine dihydrochloride is the salt usually employed for the preparation of injections.

CONTRA-INDICATIONS:
Quinine is contra-indicated in patients with a history of hypersensitivity to quinine especially if it takes the form of cutaneous, angioedematous, visual or auditory symptoms. It is also contra-indicated in the presence of haemolysis, and in patients with tinnitus or optic neuritis.

WARNINGS:
Quinine must be used with caution in patients with atrial fibrillation or other serious heart disease.
Quinine may aggravate symptoms of myasthenia gravis and should be used with care if at all in such patients.
Quinine may cause hypoprothrombinaemia and enhance the effects of anticoagulants. Quinine must be stopped immediately if evidence of haemolysis appears.
Antimalarial agents and especially quinine, when given for prolonged periods, have been implicated in precipitating black water fever. However, in some cases deficiency of glucose-6-phosphate dehydrogenase may have been involved. Glucose-6-phosphate dehydrogenase- deficient patients with malaria may be at increased risk of haemolysis during quinine therapy.
For use in pregnancy, refer 'Dosage and Directions for Use'.

DOSAGE AND DIRECTIONS FOR USE:
In severe or complicated malaria, when the patient is unable to take oral medication, a slow intravenous infusion of quinine is used.
In severely ill adults, a loading dose of 20 mg quinine dihydrochloride per kg may be administered by slow, constant rate intravenous infusion diluted in either isotonic fluid or 5% glucose solution (5-10 mL per kg bodyweight depending on the patient's overall fluid balance) over four hours provided that the patient has not received quinine, quinidine or mefloquin during the previous twelve to twenty-four hours, and reliable hospital facilities are available, including cardiac monitoring.
The maintenance dose is 10 mg of quinine dihydrochloride per kg in 250 to 500 mL of diluent, preferably 5% glucose solution, by intravenous infusion over four hours, repeated at eight to twelve hourly intervals.
For children, a dose of 25 to 30 mg per kg body-mass daily in three divided doses has been recommended.
Oral therapy should be substituted as soon as possible and a total of at least seven days therapy should be completed.
If, after forty-eight hours of parenteral treatment, the patient is still unable to take oral treatment, or if there is evidence of significant hepatic impairment, the maintenance dose should be reduced by half. The recommended drug dosage adjustment for patients with impaired renal function (ie. a GFR less than 10), is a third of the normal dose. However, the loading dose of quinine should not be reduced in patients with renal and hepatic impairment.
If intravenous infusion is not possible, quinine dihydrochloride may be given by intramuscular injection of 10 mg per kg, although this may cause pain and local tissue necrosis.
Monitoring of blood levels and side-effects is recommended during quinine therapy.
NB: Quinine should never be given by rapid intravenous "push" or bolus injections as this may cause severe or even fatal cardiovascular toxicity.
Pregnancy:
Quinine should not be withheld from pregnant women with life-threatening malaria if other less hazardous agents are unavailable or inappropriate. Pregnant women seem to be particularly prone to quinine-induced hyperinsulinaemia and hypoglycaemia. Excessive doses may induce abortion, and congenital malformation of the optic and auditory nerves have been reported after failure to induce abortion with quinine.
When administered intravenously to pregnant patients, the infusion rate should not exceed 10 mg/kg every eight hours.

SIDE-EFFECTS AND SPECIAL PRECAUTIONS:
Cinchonism
Repeated doses of quinine in normal therapeutic doses may give rise to a cluster of symptoms known as cinchonism.
In mild form this consists of ringing in the ears, headache, nausea and disturbed vision; however when medication is continued or after large single doses, gastro-intestinal, cardiovascular and dermal manifestations may appear.
Hearing and vision are particularly disturbed. Functional impairment of the 8th nerve results in tinnitus, decreased auditory acuity, and vertigo. Visual signs consist of blurred vision, disturbed colour perception, photophobia, diplopia, night blindness, constricted visual fields, scotomata, mydriasis and rarely blindness. Marked spastic constriction of the retinal vessels occurs; the retina is ischaemic, the discs are pale and retinal oedema may ensue. In severe cases, optic atrophy results.
Visual disturbances are normally reversible but may be permanent, and may rarely include sudden blindness.
Gastro-intestinal symptoms are also prominent in cinchonism. Nausea, vomiting, abdominal pain and diarrhoea result from local irritation, and the nausea and emesis also have a central basis.
The skin is often hot and flushed, and sweating is prominent. Rashes frequently appear. Angioedema, especially of the face, is occasionally observed.
Hypersensitivity
Some patients are hypersensitive to quinine and even small doses may give rise to cinchonism together with other hypersensitivity reactions including angioedema and asthma.
Renal Damage
Renal damage may occur and anuria and uremia may ensue. Renal impairment may be due to an immune mechanism or to circulatory failure.
The triad of massive haemolysis, haemoglobinaemia, and haemoglobinurea is a rare complication of quinine therapy in pregnant women or in patients with malaria.
Quinine is capable of causing hypoprothrombinaemia; the simultaneous administration of vitamin K counteracts the prolongation of the prothrombin time. Rarely, quinine may cause thrombocytopenic purpura in susceptible individuals by a thrombocytolytic action. In a few instances, the drug appears to have caused agranulocytosis.
Cardiovascular Symptoms
Quinine may cause disturbances in cardiac conduction and a reduction of blood pressure with syncope and circulatory failure; severe hypotension can also follow rapid injection of quinine.
Transient ventricular tachycardia may rarely be observed after massive acute overdosage.

KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT:
Poisoning by quinine is usually due to clinical overdose or to hypersensitivity. Symptoms of overdosage include gastro-intestinal, central nervous system, cardiovascular disturbances, and other toxic symptoms mentioned under side-effects to an enhanced degree. Visual disturbances are usually reversible but may be permanent, and may rarely include sudden blindness.
CNS Symptoms
These are noted in more severe grades of poisioning, particularly headache, fever, vomiting, apprehension, excitement, confusion, delirium, and syncope.
Respiration is first stimulated and then shallow and depressed. The skin becomes cold and cyanotic as poisoning progresses, the body temperature and blood pressure fall, weakness is extreme and the pulse is feeble, coma ensues and death occurs from respiratory arrest.
Severe poisoning can produce convulsions, coma, respiratory depression and death.
The average fatal dose in adults has been reported to be about 8 g. Death may result in a few hours or may be delayed for one to two days.
If large doses of quinine or its salts have been recently ingested, the stomach should be emptied by aspiration and lavage.
Measures aimed at enhancing the elimination of quinine such as forced acid diuresis, haemodialysis, and haemoperfusion are largely ineffective because quinine is extensively metabolized in the liver.
Blood pressure should be supported. Signs of haemolytic anaemia may be indicative of a need to treat acute renal failure.
Assisted respiration may be neccessary to combat respiratory failure.
Cardiac rhythm should be monitored.

IDENTIFICATION:
1 mL ampoules of clear, pale yellow liquid.

PRESENTATION:
1 mL ampoules in packs of 10.

STORAGE INSTRUCTIONS:
Store below 25°C. Protect from light. Keep out of reach of children.

REGISTRATION NUMBER:
E/12/43

NAME AND BUSINESS ADDRESS OF THE APPLICANT:
ADCOCK INGRAM LIMITED
Adcock Ingram Park
17 Harrison Avenue
Bryanston
Private Bag X69, Bryanston, 2021

DATE OF PUBLICATION OF THIS PACKAGE INSERT:
February 1973

New addition to this site: April 2004
Source: Pharmaceutical Industry

SAEPI HOME PAGE      TRADE NAME INDEX      GENERIC NAME INDEX      FEEDBACK
Information presented by Malahyde Information Systems © Copyright 1996-2004